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Abstract
Background: In 2006, the Vermont Oxford Network (VON) established the Neonatal Encephalopathy Registry (NER)
to characterize infants born with neonatal encephalopathy, describe evaluations and medical treatments, monitor
hypothermic therapy (HT) dissemination, define clinical research questions, and identify opportunities for
improved care.
Methods: Eligible infants were≥ 36 weeks with seizures, altered consciousness (stupor, coma) during the first
72 hours of life, a 5 minute Apgar score of≤ 3, or receiving HT. Infants with central nervous system birth defects
were excluded.
Results: From 2006–2010, 95 centers registered 4232 infants. Of those, 59% suffered a seizure, 50% had a 5 minute
Apgar score of≤ 3, 38% received HT, and 18% had stupor/coma documented on neurologic exam. Some infants
experienced more than one eligibility criterion. Only 53% had a cord gas obtained and only 63% had a blood gas
obtained within 24 hours of birth, important components for determining HT eligibility. Sixty-four percent received
ventilator support, 65% received anticonvulsants, 66% had a head MRI, 23% had a cranial CT, 67% had a full channel
encephalogram (EEG) and 33% amplitude integrated EEG. Of all infants, 87% survived.
Conclusions: The VON NER describes the heterogeneous population of infants with NE, the subset that received
HT, their patterns of care, and outcomes. The optimal routine care of infants with neonatal encephalopathy is
unknown. The registry method is well suited to identify opportunities for improvement in the care of infants
affected by NE and study interventions such as HT as they are implemented in clinical practice.
Keywords: Hypoxic ischemic encephalopathy, Neonatal encephalopathy, HIE, Therapeutic hypothermia, Asphyxia,
Cooling, Neuroprotection, Neonatal encephalopathy, Registry
Background
Neonatal encephalopathy (NE) in the term or late pre-
term infant is "a clinically defined syndrome of disturbed
neurologic function in the earliest days of life manifested
by difficulty with initiating and maintaining respiration,
depression of tone and reflexes, subnormal level of con-
sciousness, and often by seizures" [1]. NE occurs in an
estimated 2–5 per 1000 live term births of which up to
one quarter experience moderate or severe cerebral in-
jury [2-4]. Between 10-40% do not survive and as many
as 30% exhibit significant long-term neurodevelopmental
disability [5].
Randomized controlled trials (RCTs) demonstrated
that hypothermic therapy (HT) may improve neurologic
and developmental outcomes and reduce death and dis-
ability in term infants with NE [6-9]. As a result, many
practitioners have lost equipoise [10,11]. The National
Institute of Child Health and Human Development and
the American Academy of Pediatrics Committee on
Fetus and Newborn caution that clinicians should follow
published trial protocols, ensure systematic follow-up of
survivors, and submit patient data to registries when
using HT outside of a trial [12,13]. Registries, by docu-
menting the natural history of enrolled patients as they
present for care, monitor clinical patterns and patient
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outcomes in rare disorders such as NE and track the
“real world” dissemination of a novel therapy like HT [14].
The Vermont Oxford Network (VON) is a non-profit
voluntary collaboration of health care professionals dedi-
cated to improving the quality and safety of medical care
for newborn infants and their families at over 850 neo-
natal intensive care units (NICU) around the world. The
VON Neonatal Encephalopathy Registry (NER) was
established in 2006.
The primary objective is to characterize infants born
with NE, including perinatal and antenatal risk factors,
how these infants are identified, the evaluations and
treatments they receive, and their outcomes. Secondary
objectives include monitoring the dissemination and up-
take of the novel therapies such as HT and description
of variation of care applied to NE infants. These data
will help define clinical research questions and identify
opportunities for improved care of NE. This manuscript
describes the methods and basic demographic results of
the VON NER.
Methods
Hospitals could enroll patients in the NER through par-
ticipation in one of two databases maintained by VON.
The very low birth weight (VLBW) database includes
any infant born alive at a participating hospital with a
birth weight 401–1500 grams or a gestational age of 22–
29 weeks regardless of where the infant receives care, as
well as any outborn infant meeting these criteria admit-
ted to any location in the hospital within 28 days of birth
without first having gone home. The Expanded database
includes any infant regardless of birth weight or gesta-
tional age admitted to the hospital’s NICU by day 28.
In 2006 and 2007, only VON Expanded database
centers could participate in the NER. Beginning in
2008, all VON database participating centers were eli-
gible. Participation in the NER requires no additional
fee. VON uses these data for research and reporting,
but maintains the confidentiality of individual hospital
data. Participating hospitals receive reports comparing
their local data with the Registry as a whole. A partici-
pating NER center submitted data on one or more eli-
gible infants.
Infant eligibility
Any infant born at 36 weeks gestation or more display-
ing evidence of NE within 3 days of birth is eligible. NE
is defined as presence of seizures and/or altered con-
sciousness (stupor, coma). In order to cast a wide net
that captures all infants potentially affected by NE inde-
pendent of the adequacy of their neurologic exam,
infants with a 5 minute Apgar score of ≤ 3 are included.
Accordingly, infants that received neuromuscular
blockade are also eligible since their level of conscious
could not be assessed. Regardless of neurologic status,
any infant that received HT is eligible. Infants born with
central nervous system (CNS) birth defects are excluded
(Figure 1).
Data items
The VON NER Steering Committee chose data items
to characterize the population of all infants with NE,
identify potential antecedents, evaluate variations in
current practice, and monitor the dissemination of HT
and adherence to the RCT efficacy standards. Data items
include: patient identifiers, patient selection criteria, in-
fant characteristics, treatments and tests, and outcomes
at time of disposition. Where possible, data forms follow
standards and terminology derived from existing studies
to contribute to evolving medical knowledge. Participat-
ing centers receive explicit data definitions for each
variable to ensure internal validity and uniform data ac-
quisition. A complete catalogue of data items and defini-
tions are in the manual of operations published on the
VON website: http://www.vtoxford.org/tools/downloads.
aspx.
Centers collect and submit data using freely provided
VON eNICQ software, which provides easy to use
on-screen data definitions, immediate feedback on issues
such as missing or out-of-range values, and error check-
ing for logical inconsistencies. VON staff members per-
form additional data assessment and contact hospitals
about missing data items, unresolved records, out-of-
range values, and appropriate modifications as indicated.
Only de-identified data are submitted to VON.
The Registry does not dictate patient care, propose
any interventions, or endorse any protocols for treat-
ment. Each infant receives care according to the stan-
dards of that institution. There is no expected increased
risk for participation of individual patients and only de-
identified data are submitted. The University of Vermont
and State Agricultural College Committee on Human
Research in the Medical Sciences (CHRMS) Institutional
Review Board (IRB) at the University of Vermont
granted ethical approval for the methods of the NER
(reference number CHRMS 06–100). Additionally, par-
ticipating hospitals gained local IRB approval for the
participation in the Registry. VON requires documenta-
tion of each participating center’s local IRB approval be-
fore participation in the Registry. Submitted data
becomes the property of VON. The Network may use
these data for research and reporting, but maintains
the confidentiality of individual hospital data.
Outcomes of interest in the NER include death prior
to hospital discharge, survivor disposition status, neuro-
logic course, presence of seizures, common neonatal
co-morbidities, and adverse events associated with HT
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including the following: arrhythmia, thrombosis, severe
hypotension, seizure during re-warming, scalp edema, skin
breakdown, sclerema neonatorum, thrombocytopenia, and
infection. These outcomes will be addressed in future
NER studies.
Data analysis
We summarized demographic and clinical characteristics
with percentages for categorical variables, mean (and
standard deviation) for normally distributed variables,
and median (and interquartile range) for other continu-
ous variables. Hospital characteristics come from the
VON Annual Survey.
Results
Hospital participation
From 2006 to 2010, 95 centers registered infants in the
NER (Table 1). Participating hospitals averaged 686
(Quartile 1 (Q1): 473, Quartile 3 (Q3): 830) annual
NICU admissions. A complete list of participating hospi-
tals is presented in Table 2. We averaged each center’s
annual volume across all of the years in which the center
submitted NER records. The mean number of infants
that met eligibility requirements per center was 44.5
(Q1: 15.0, Q3: 57.0).
Almost all (97%) NER centers were non-profit
(Table 3). Minority-serving hospitals, those that treat
>35% black infants, [15] constituted 18% of the partici-
pating hospitals. Over three-fourths of the participating
centers had pediatric residents or neonatology fellows
working within their NICUs. Almost all centers had
MRI scanning capability.
VON classifies participating NICUs using a method
based on the AAP Levels of Neonatal Care classification
Table 1 Growth of Vermont Oxford Network National
Encephalopathy Registry: Participating centers and
infants per year, 2006-2010
Year of birth Number of centers Number of infants
2006 41 433
2007 37 547
2008 62 813
2009 87 1229
2010 85 1210
2006-2010 95 4232
Figure 1 Registry Eligibility and Infant Characteristics.
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Table 2 Hospitals registering infants in the Vermont Oxford Network Neonatal Encephalopathy Registry, 2006–2010
Name City State Country
Cork University Maternity Hospital Cork Ireland
National Maternity Hospital Dublin Ireland
Rotunda Hospital Dublin Ireland
Hospital de S. Joao Porto Portugal
Hospital Sant Joan de Deu Barcelona Spain
Latifa Hospital Dubai United Arab Emirates
Southmead Hospital Bristol United Kingdom
Arkansas Children's Hospital Little Rock Arkansas United States
UC Irvine Medical Center Orange California United States
Sharp Mary Birch Hospital for Women San Diego California United States
Santa Clara Valley Medical Center San Jose California United States
The Children's Hospital Aurora Colorado United States
Exempla St. Joseph Hospital Denver Colorado United States
Poudre Valley Health System Fort Collins Colorado United States
Yale New Haven Children's Hospital New Haven Connecticut United States
Christiana Care Health Services Newark Delaware United States
Children's Hospital of SW Florida at Lee Memorial Fort Myers Florida United States
Baptist Children's Hospital Miami Florida United States
Miami Children's Hospital Miami Florida United States
St. Joseph's Children's Hospital of Tampa Tampa Florida United States
Tampa General Hospital Tampa Florida United States
Medical Center at Columbus Regional, The Columbus Georgia United States
St. Luke's Regional Medical Center Boise Idaho United States
Evanston Hospital Evanston Illinois United States
Edward Hospital and Health Services Naperville Illinois United States
Advocate Lutheran General Hospital Park Ridge Illinois United States
Rockford Memorial Hospital Rockford Illinois United States
St. John's Hospital Springfield Illinois United States
Carle Foundation Hospital Urbana Illinois United States
Central DuPage Hospital Winfield Illinois United States
St. Luke's Hospital Cedar Rapids Iowa United States
Blank Children's Hospital Des Moines Iowa United States
Overland Park Regional Medical Staff Overland Park Kansas United States
Wesley Medical Center Wichita Kansas United States
Kosair Children's Hospital Louisville Kentucky United States
Woman's Hospital Baton Rouge Louisiana United States
Eastern Maine Medical Center Bangor Maine United States
Barbara Bush Children's at Maine Medical Portland Maine United States
University of Maryland Division of Neonatology Baltimore Maryland United States
Frederick Memorial Hospital Frederick Maryland United States
Massachusetts General Hospital for Children Boston Massachusetts United States
UMass Memorial Healthcare Worcester Massachusetts United States
U. of MI, CS Mott Children's, Brandon NICU Ann Arbor Michigan United States
Henry Ford Hospital Detroit Michigan United States
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Table 2 Hospitals registering infants in the Vermont Oxford Network Neonatal Encephalopathy Registry, 2006–2010
(Continued)
DeVos Children's, Spectrum Health Grand Rapids Michigan United States
Sparrow Hospital Lansing Michigan United States
University of MN Children's Hospital, Fairview Minneapolis Minnesota United States
North Memorial Medical Center Robbinsdale Minnesota United States
St. Cloud Hospital Saint Cloud Minnesota United States
St. Francis Medical Center, Cape Girardeau Cape Girardeau Missouri United States
Cardinal Glennon Children's Hospital St. Louis Missouri United States
St. Louis Children's Hospital St. Louis Missouri United States
St. Elizabeth Regional Medical Center Lincoln Nebraska United States
Alegent Health Bergen Mercy Medical Center Omaha Nebraska United States
Nebraska Medical Center Omaha Nebraska United States
Albany Medical Center Albany New York United States
Weiler Hospital Montefiore Bronx New York United States
Winthrop University Hospital Mineola New York United States
Columbia University Medical Center New York New York United States
Golisano Children's Hospital at Strong Rochester New York United States
Mission Children's Hospital Asheville North Carolina United States
Duke University Durham North Carolina United States
Cape Fear Valley Medical Center Fayetteville North Carolina United States
Women's Hospital of Greensboro Greensboro North Carolina United States
Pitt County Memorial Hospital Greenville North Carolina United States
WAKEMED Faculty Physicians, Wake Medical Center Raleigh North Carolina United States
Brenner Children's Hospital at WFUBMC Winston-Salem North Carolina United States
Akron Children's Hospital Akron Ohio United States
Children's Hospital Medical Center Cincinnati Cincinnati Ohio United States
Henry Zarrow Neonatal Intensive Care Unit Tulsa Oklahoma United States
Rogue Valley Medical Center Medford Oregon United States
Providence St. Vincent Medical Center Portland Oregon United States
Randall Children's Hospital at Legacy Emanuel Portland Oregon United States
Salem Hospital Salem Oregon United States
Sacred Heart Medical Center Springfield Oregon United States
St. Luke's University Hospital Bethlehem Pennsylvania United States
Geisinger Medical Center Danville Pennsylvania United States
Penn State Children's Hospital Hershey Pennsylvania United States
Thomas Jefferson University Hospital Philadelphia Pennsylvania United States
Magee Women's Hospital Pittsburgh Pennsylvania United States
Palmetto Health Richland Columbia South Carolina United States
Children's Hospital of Greenville Greenville South Carolina United States
University of Tennessee Medical Center Knoxville Tennessee United States
Baptist Memorial Hospital for Women Memphis Tennessee United States
Monroe Carell Jr. Children's Hospital Vanderbilt Nashville Tennessee United States
Cook Children's Medical Center Fort Worth Texas United States
Christus Santa Rosa Healthcare San Antonio Texas United States
Methodist Children's Hospital San Antonio Texas United States
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set forth by the Committee on Fetus and Newborn [16].
The VON annual survey does not differentiate between
Level IIIC (those that provide major surgical services ex-
cluding serious congenital heart anomalies that require
cardiopulmonary bypass or extracorporeal membrane
oxygenation (ECMO)) and Level IIID hospitals (those
that do provide major surgery including surgical repair
of serious congenital heart anomalies or ECMO). All
NER hospitals classified themselves in the annual survey
as subspecialty intensive care (level III) hospitals. The
majority (52%) were level IIIB hospitals, which have no
restrictions on the duration of mechanical ventilation
but do not provide major surgery.
Infant eligibility
Of the 4232 eligible infants, 59% suffered a clinically ap-
parent seizure within the first 72 hours of life, 50% had a
5 minute Apgar score of 3 or less, 38% had HT, 18% had
stupor/coma, and 2% had neuromuscular blockade. HT
as the sole eligibility criteria accounted for 8% of the en-
tire sample. Many infants (39%) experienced more than
one eligibility criterion. Among infants with multiple eli-
gibility criteria, 30.7% received hypothermia, 28.1% had
an Apgar score of 3 or less, 26.9% had a clinically appar-
ent seizure, 17.2% had stupor or coma, and only 1.2%
had neuromuscular blockade.
Infant characteristics
Registered infants had a median birth weight of
3298 grams (Q1: 2905, Q3: 3685) and a median gesta-
tional age of 39 weeks (Q1: 38, Q3: 40). Over one-third
of infants were not admitted to the NICU until 6 hours
after birth (Table 4). Of those not admitted until after
6 hours, 81% were outborn. Sixteen percent were small
for gestational age. Over 60% of infants required trans-
port. Over half (56%) were delivered by cesarean section
(C/S), the majority of which had a trial of labor before
the C/S. Fourteen percent of infants had a traumatic
birth injury. A cord gas was obtained at the time of de-
livery in 53% of enrolled infants. Of those obtained, the
Table 3 Hospital Characteristics in Vermont Oxford
Network Neonatal Encephalopathy Registry
Characteristic* Number of hospitals %
Non-profit 92 96.8
Minority Serving Hospital 17 17.9
Teaching Hospital 72 75.8
Children’s Hospital 15 15.8
MRI Scanning Capability 92 96.8
AAP Level IIIA 9 9.5
AAP Level IIIB 49 51.6
AAP Level IIIC and IIID 33 34.7
AAP Level Unknown 4 4.2
*Based on the last year in which the center submitted NER data.
Table 2 Hospitals registering infants in the Vermont Oxford Network Neonatal Encephalopathy Registry, 2006–2010
(Continued)
Vermont Children's at Fletcher Allen Health Care Burlington Vermont United States
Carilion Clinic Children's Hospital Roanoke Virginia United States
Swedish Medical Center Seattle Washington United States
West Virginia University School of Medicine Morgantown West Virginia United States
Gundersen Lutheran Medical Center LaCrosse Wisconsin United States
St. Mary's Hospital Medical Center Madison Wisconsin United States
Wheaton Franciscan Healthcare at St. Joseph Milwaukee Wisconsin United States
Table 4 Characteristics of Infants in Vermont Oxford
Network National Encephalopathy Registry, 2006-2010
Eligible N %
Admission Time> 6hrs 4165 1395 33.5
Small for Gestational Age 4231 676 16.0
Inborn 4232 1682 39.7
Maternal Race 4194
Asian 95 2.3
Black 777 18.5
Hispanic 574 13.7
White 2675 63.8
Other 73 1.7
Number of Births 4232
Singleton 4167 98.5
Twins 65 1.5
Delivery Method 4228
Spontaneous vaginal 1414 33.4
Vaginal delivery using vacuum/forceps 450 10.6
Cesarean section before labor 840 19.9
Cesarean section after labor 1524 36.1
Traumatic Birth Injury 4206 590 14.0
Meconium Aspiration Syndrome 4227 515 12.2
Cord Gas Obtained* 3699 1946 52.6
*The NER specified arterial cord blood gas from 2006–2008 but in 2009–2010
included umbilical cord blood from any source.
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mean pH was 7.0 (Q1: 6.9, Q3: 7.2) and the mean cord
gas base excess was −12.2 (Q1: -17.6, Q3: -6.0).
Evaluations and treatments
Of NER infants, 64% received ventilator support, 38%
received HT, and 65% received anticonvulsants for any
indication (Table 5). Thirteen percent received inhaled
nitric oxide and 3% received ECMO. Approximately 9%
of the infants had surgery during their hospitalization,
mainly abdominal. Sixty-six percent of infants under-
went a head MRI and 49% received a cranial ultrasound.
Sixty-seven percent had a full channel encephalogram
(EEG) while 33% underwent amplitude integrated EEG
monitoring. Overall, 36% of infants did not have a blood
gas obtained from any site (arterial, venous, or capillary).
Of those infants with a value, the worst gas results
yielded a mean pH of 7.1 (Q1: 7.0, Q3: 7.3) and a mean
base excess of −13.0 (Q1: -20.0, Q3: -6.0).
Outcomes
Of all infants, 87% survived (Table 6). Among the survi-
vors, at discharge 38% were on anticonvulsants, 86%
received all feeds by mouth, 6% had home monitoring,
and 1% had ventilator support. The typical length of stay
among surviving infants discharged to home was 11 days
(Q1: 7, Q3: 19). Of infants that died during their initial
hospitalization, the median day of death was day 4 (Q1:
2, Q3: 9).
Discussion
A patient registry is an organized system that uses obser-
vational study methods to collect uniform data and
evaluate specified outcomes for a population defined by
a particular disease, condition, or exposure, and that
serves a predetermined scientific, clinical, or policy pur-
pose(s) [17]. Registries can support clinical conditions,
health care services, or products, and can address ques-
tions ranging from treatment effectiveness and safety to
the quality of care delivered.
The VON NER captures data and characterizes infants
with NE and a subset treated with HT. To increase ex-
ternal validity, inclusion criteria for the VON NER are
intentionally few and simple: the presence of seizures
and/or altered consciousness (stupor, coma) during the
first 72 hours of life. Additional inclusion parameters
capture all potentially encephalopathic infants treated
with hypothermia independent of their neurologic status
and infants whose neurologic status might be difficult
to assess (e.g., paralyzed, mechanically ventilated, or
sedated infants).
Historically, the presence of NE has been considered
sine qua non of hypoxic-ischemic injury or birth as-
phyxia. However, the etiology of NE is not limited to
Table 6 Outcomes at initial disposition of all infants in
the Vermont Oxford Network National Encephalopathy
Registry, 2006-2010
Elig N %
Survival status
Died 4232 551 13.0
Alive 4232 3676 86.9
Unknown 4232 5 0.1
Among Survivors
Anticonvulsants at discharge 3670 1393 38.0
Feeds at discharge
Enteral, all by mouth 3670 3141 85.6
Enteral, none by mouth 3670 259 7.1
Some by mouth 3670 201 5.5
No enteral feeding 3670 69 1.9
Hearing screen passed 3212 2942 91.6
Discharged home
On monitor 3439 220 6.4
On oxygen 3441 132 3.8
On ventilator 3676 50 1.4
Table 5 Evaluations and treatments received by infants in
the Vermont Oxford Network National Encephalopathy
Registry, 2006-2010
Elig N %
Therapeutic hypothermia 4232 1626 38.4
Anticonvulsant during hospital course 4177 2715 65.0
Blood gas obtained within 24 hours1 1723 1083 62.9
Blood gas obtained within first hour2 2281 1462 64.1
Cranial ultrasound 4172 2045 49.0
Cranial CT 4168 951 22.8
MRI 4170 2742 65.8
Full channel EEG 4171 2777 66.6
Amplitude integrated EEG (aEEG) 4168 1376 33.0
High flow nasal cannula (HFNC) 4167 1371 32.9
Nasal CPAP 4168 748 18.0
Ventilator 4168 2723 65.3
High frequency oscillatory ventilation (HFOV) 4168 486 11.7
Extracorporeal membrane oxygenation (ECMO) 4167 118 2.8
Inhaled nitrous oxide (iNO) 4167 556 13.3
Any Surgery 4168 379 9.0
Cardiac 4168 22 0.5
PDA 4168 9 0.2
Abdominal 4168 301 7.2
CNS 4168 25 0.6
1Question for 2006–2008.
2Question for 2009–2010.
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hypoxic-ischemic injury and displays considerable diver-
sity [18]. Only a small proportion of infants in the NER
had documented exposure to acute intrapartum asphyxia
(“sentinel events”). These findings reflect previous re-
search suggesting that a minority (25-35%) of cases of
NE attributed to birth asphyxia have a clear contributing
sentinel event in the intrapartum period [13,19]. The
VON NER is being used describe the frequency with
which recognized antecedents of NE occurred in a large
sample of encephalopathic term newborns. These find-
ings will have implications for future studies of the eti-
ology of NE.
Timely recognition of NE infants affected by HIE is
crucial to the success of HT. Very few infants in the
Registry were identified as having altered consciousness
on neurologic exam. In fact, the most common route
for entry was following a seizure. Among the subset of
NE infants caused by HIE, by the time an infant suf-
fers seizures it may be too late to achieve the full
benefit of HT [20,21]. Given that birth asphyxia is
often presumed the etiology of NE, it is striking to
note that umbilical cord blood gas examinations were
obtained in just over half of the infants during their
perinatal courses. Similarly, less than 40% of the
infants had blood gas sampling performed following
birth. Since neurologic exams and umbilical and cord
blood gas examinations are commonly used tests to
determine whether or not HT is appropriate, these
data suggest there is room for improvement in the
recognition and evaluation of NE.
Nearly four in ten (38%) NER infants were eligible due
to exposure to HT. However the majority were also
encephalopathic and in only a small percentage (8%) was
HT the sole criteria for eligibility. One third of infants
receiving HT were admitted after 6 hours of life when
any neuroprotective benefit from HT may be dimin-
ished. Over 60% of NE infants required transport, which
may be a significant contributing factor in the observed
delay in admission. Identification of gaps between the
conditions for implementation of HT in clinical trials
and in what is observed in clinical practice and identifi-
cation of areas of improvement are focused areas of on-
going NER research.
The optimal routine evaluation and treatments of
infants with NE is unknown. The majority of infants
were treated with anticonvulsants but significant vari-
ation was noted in the approach to electroencephalo-
graphic monitoring. Only 66% had optimal imaging
(head MRI) and 23% underwent a suboptimal exam
(head CT) according to accepted quality standards [22].
Ongoing work of the NER will identify and document
variation in the evaluations and medical treatments
these infants receive, providing valuable information for
future RCTs.
Variation in patient selection and adherence to estab-
lished protocols contributes to differences in survival,
adverse events, and long-term outcomes for treated
infants [23,24]. Among infants in the NER, 13% died, a
proportion similar to the mortality rate of NE observed
in a population based report by Badawi et al. (9%) des-
pite different inclusion criteria [3]. Of infants that sur-
vived to discharge, a significant proportion required
ventilation, monitoring, and other medical care at
home. These findings are consistent with previous
observations of the medical burden and mortality asso-
ciated with NE infants and underscores the need for
improvement of the quality of care. The NER provides
benchmarking data that member centers use while par-
ticipating in VON multicenter quality improvement
collaborations.
A large proportion of cerebral palsy, cognitive dis-
ability, and epilepsy arise in infants born at term or
late preterm [25]. In contrast to preterm infant births,
the births of term and late preterm infants are scat-
tered over a broad range of facilities, many of which
care for relatively few infants each year with NE.
NER hospitals may be the best representation of those
caring for encephalopathic infants in the “real world”
and represent a generalizable view of HT as it occurs
outside the academic sector or in a research setting.
VON NER centers are heterogeneous in terms of size
and numbers of infant records submitted. However,
the participating nurseries were largely non-profit ter-
tiary referral centers. Slightly more than half were
teaching hospitals.
The UK TOBY Cooling Register also captures data on
neonatal HT [26,27]. The TOBY Register started after the
TOBY trial of HT closed enrollment, upon recognition that
many physicians were offering HT out of the context of
any trial [6,28]. It is a phase 4 study of the specific methods
of the trial, with a narrower set of inclusion criteria than
the VON NER. Comparison of information in the VON
and the TOBY registries will be useful in understanding
dissemination of HT when implemented strictly in accord-
ance with a previous trial (TOBY) versus in a more broad
clinical setting (VON NER).
Limitations
Registries have important limitations with respect to
RCTs. RCTs have strong internal validity, but often are
focused on a relatively homogeneous group of patients
from whom significant numbers are excluded at the
cost of external validity or widespread generalizability.
Registries aim for greater generalizability with populations
relevant to all clinical settings. The nature of registry data
limits clinicians from applying registry data to clinical
decision-making. However, careful data collection and ana-
lyses of the NER, with oversight by the Steering Committee,
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aim to limit the potential for bias and misinterpretation of
data. Awareness and recognition of bias in registry data
adds to its heuristic value for planning clinical research or
guiding NICU policies.
Conclusion
A registry is well suited to the study of the heterogeneous
population of NE infants and to the characterization of
how interventions such as HT are implemented in clinical
practice. This manuscript describes the methods and ini-
tial demographic results of the VON NER. Future manu-
scripts are planned on antecedents of NE, evaluation and
treatment of neonatal seizure, optimal neuroimaging of
NE infants, and hypothermia for HIE in routine practice.
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